-45.4%
BA vs MRNA
+915.3%
-960.7%
-77.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -3.4% | +3.4% | +0.1% |
| 7D | -1.1% | -12.1% | +11.0% | -0.6% |
| 30D | -7.1% | -1.3% | -5.8% | -7.2% |
| 3M | -25.5% | +250.9% | -276.5% | -31.4% |
| 6M | -28.7% | +343.0% | -371.7% | -35.5% |
| YTD | -21.0% | +657.4% | -678.5% | -31.2% |
| 1Y | -11.9% | +794.9% | -806.8% | -24.1% |
| 3Y | -16.2% | +218.1% | -234.3% | -24.7% |
| 5Y | -22.4% | -3.4% | -19.0% | -29.2% |
| All | -45.4% | +915.3% | -960.7% | -49.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling